In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients.
We performed in vitro antifungal checkerboard testing on 12 Aspergillus fumigatus clinical isolates (6 transplant recipients and 6 nontransplant patients) with three antifungal agents (amphotericin B, voriconazole, and caspofungin) and three immunosuppressants (FK506, cyclosporine, and rapamycin). We were not able to detect a difference in calcineurin inhibitor antifungal activity against isolates from transplant recipients and nontransplant patients.
Steinbach
William J
WJ
Division of Pediatric Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA. stein022@mc.duke.edu
Singh
Nina
N
Miller
Jackie L
JL
Benjamin
Daniel K
DK
Schell
Wiley A
WA
Heitman
Joseph
J
Perfect
John R
JR
D000666:Amphotericin B / Q000494:pharmacology; D000935:Antifungal Agents / Q000494:pharmacology*; D001228:Aspergillosis / Q000188:drug therapy*; D001232:Aspergillus fumigatus / Q000187:drug effects*; D065095:Calcineurin Inhibitors; D000077336:Caspofungin; D016572:Cyclosporine / Q000494:pharmacology; D054714:Echinocandins; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D055666:Lipopeptides; D016377:Organ Transplantation; D010456:Peptides, Cyclic / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D016559:Tacrolimus / Q000494:pharmacology; D014230:Triazoles / Q000494:pharmacology; D065819:Voriconazole
D000935:Antifungal Agents; D065095:Calcineurin Inhibitors; D054714:Echinocandins; D007166:Immunosuppressive Agents; D055666:Lipopeptides; D010456:Peptides, Cyclic; D011743:Pyrimidines; D014230:Triazoles; D000666:Amphotericin B; D016572:Cyclosporine; D000077336:Caspofungin; D065819:Voriconazole; D016559:Tacrolimus